Reboxetine
Reboxetine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium-dependent noradrenaline transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| behavior and behavior mechanisms | D001520 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 7 | — | 1 | — | 8 |
| Depression | D003863 | — | F33.9 | — | 1 | 1 | 2 | 3 | 7 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | 1 | 3 | 5 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | 1 | 3 | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | 1 | 1 | — | 3 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | — | 1 | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | 1 | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Panic disorder | D016584 | EFO_0004262 | F41.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 3 | — | — | 4 |
| Narcolepsy | D009290 | HP_0030050 | G47.4 | — | 1 | 2 | — | — | 3 |
| Cataplexy | D002385 | HP_0002524 | — | — | 1 | 2 | — | — | 3 |
| Sleepiness | D000077260 | — | R40.0 | — | 1 | 2 | — | — | 3 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | 3 | — | — | 3 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | — | 2 | — | — | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 2 | — | — | — | 3 |
| Stress urinary incontinence | D014550 | HP_0010992 | — | 1 | 2 | — | — | — | 3 |
| Enuresis | D004775 | — | R32 | 1 | 2 | — | — | — | 3 |
| Peripheral nervous system diseases | D010523 | HP_0009830 | G64 | — | 2 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | — | — | 1 |
| Hyperkinesis | D006948 | HP_0000752 | — | — | 1 | — | — | — | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | — | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fecal incontinence | D005242 | — | R15 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 4 | 4 |
| Decision making | D003657 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Reboxetine |
| INN | reboxetine |
| Description | Reboxetine is an aromatic ether. |
| Classification | Small molecule |
| Drug class | antidepressants (fluoxetine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccccc1OC(c1ccccc1)C1CNCCO1 |
Identifiers
| PDB | — |
| CAS-ID | 105017-38-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL14370 |
| ChEBI ID | — |
| PubChem CID | 127151 |
| DrugBank | DB00234 |
| UNII ID | 947S0YZ36I (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,457 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
430 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use